"beta 2-Glycoprotein I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.
| Descriptor ID |
D053482
|
| MeSH Number(s) |
D12.776.124.117 D12.776.395.195
|
| Concept/Terms |
beta 2-Glycoprotein I- beta 2-Glycoprotein I
- beta 2 Glycoprotein I
- Apo H
- Endothelial Cell-Viability Maintaining Factor
- Endothelial Cell Viability Maintaining Factor
- beta(2)GPI
- beta2-Glycoprotein I
- beta2 Glycoprotein I
- EC-VMFa
- EC VMFa
- Anticardiolipin Cofactor
- Cofactor, Anticardiolipin
- Apolipoprotein H
|
Below are MeSH descriptors whose meaning is more general than "beta 2-Glycoprotein I".
Below are MeSH descriptors whose meaning is more specific than "beta 2-Glycoprotein I".
This graph shows the total number of publications written about "beta 2-Glycoprotein I" by people in this website by year, and whether "beta 2-Glycoprotein I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "beta 2-Glycoprotein I" by people in Profiles.
-
Gkrouzman E, Willis R, Andrade D, Tektonidou MG, Pengo V, Ruiz-Irastorza G, Belmont HM, Fortin PR, Gerosa M, Signorelli F, Atsumi T, Branch DW, Nalli C, Rodriguez-Almaraz E, Petri MA, Cervera R, Knight JS, Efthymiou M, Cohen H, Bertolaccini ML, Erkan D, Roubey R. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study. Lab Invest. 2023 06; 103(6):100147.
-
Gkrouzman E, Barbhaiya M, Erkan D, Lockshin MD. Reality Check on Antiphospholipid Antibodies in COVID-19-Associated Coagulopathy. Arthritis Rheumatol. 2021 01; 73(1):173-174.
-
Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, Tektonidou MG, Ugarte A, Chighizola CB, Belmont HM, Lopez-Pedrera C, Ji L, Fortin P, Efthymiou M, de Jesus GR, Branch DW, Nalli C, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Bertolaccini ML, Cohen H, Rand J, Erkan D. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. J Rheumatol. 2021 04; 48(4):541-547.
-
Castanon A, Pierre G, Willis R, Harris EN, Papalardo E, Romay-Penabad Z, Schleh A, Jajoria P, Smikle M, DeCeulaer K, Tebo A, Jaskowski T, Guerra MM, Branch DW, Salmon JE, Petri M, Gonzalez EB. Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin. Am J Clin Pathol. 2018 Mar 29; 149(5):401-411.